Table 2.
Post-LEEP pathological findings.
| Overall (n = 436) | No residue (n = 258) | Residue (n = 178) | p-value | |
|---|---|---|---|---|
| HPV infection before LEEP | 0.12 | |||
| Negative | 87 (20%) | 57 (13.1%) | 30 (6.9%) | |
| Positive | 111 (25.5%) | 68 (15.6%) | 43 (9.9%) | |
| Other 12 positive | 108 (24.8%) | 67 (15.4%) | 41 (9.4%) | |
| 16/18 positive | 130 (29.8%) | 66 (15.1%) | 64 (14.7%) | |
| TCT before LEEP | 0.72 | |||
| NILM | 124 (28.4%) | 76 (17.4%) | 48 (11%) | |
| ASC-US | 93 (21.3%) | 59 (13.5%) | 34 (7.8%) | |
| ASC-H | 67 (15.4%) | 36 (8.3%) | 31 (7.1%) | |
| LSIL | 47 (10.8%) | 26 (6%) | 21 (4.8%) | |
| HSIL | 105 (24.1%) | 61 (14%) | 44 (10.1%) | |
| Pathology of LEEP | 0.75 | |||
| Normal or inflammation | 57 (13.1%) | 36 (8.3%) | 21 (4.8%) | |
| LSIL | 46 (10.6%) | 27 (6.2%) | 19 (4.4%) | |
| HSIL | 324 (74.3%) | 191 (43.8%) | 133 (30.5%) | |
| Suspected of an early invasive carcinoma | 9 (2.1%) | 4 (0.9%) | 5 (1.1%) | |
| LEEP internal cutting margin | 0.001 | |||
| Normal or inflammation | 234 (53.7%) | 152 (34.9%) | 82 (18.8%) | |
| LSIL | 38 (8.7%) | 27 (6.2%) | 11 (2.5%) | |
| HSIL | 164 (37.6%) | 79 (18.1%) | 85 (19.5%) | |
| LEEP outer cut margin | 0.47 | |||
| Normal or inflammation | 294 (67.4%) | 169 (38.8%) | 125 (28.7%) | |
| LSIL | 45 (10.3%) | 30 (6.9%) | 15 (3.4%) | |
| HSIL | 97 (22.2%) | 59 (13.5%) | 38 (8.7%) | |
| Gland involvement | <0.001 | |||
| NO | 332 (76.1%) | 254 (58.3%) | 78 (17.9%) | |
| Yes | 104 (23.9%) | 4 (0.9%) | 100 (22.9%) |
LEEP, loop electrosurgical excision procedure; TCT, Thinprep cytology test; NILM, Negative for intraepithelial lesion or malignancy; ASC-US, Atypical squamous cells of undetermined significance; ASC-H, Atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion; LSIL, Low-grade squamous intraepithelial lesion; HSIL, High-grade squamous intraepithelial lesion.